Intravenous Acetylsalicylic Acid – Dose-Related Effects on Platelet Function and Fibrinolysis in Healthy Males

 

PDF Download Buy Article Permissions and Reprints

Summary

Low-dose acetylsalicylic acid (ASA) has been shown to be beneficial in patients with acute myocardial infarction and unstable angina pectoris. Oral administration of ASA is difficult in the acute phase of these syndromes. In this study we evaluated the effect of 25 mg, 50 mg or 100 mg of ASA given as an intravenous bolus injection on platelet function and fibrinolysis in healthy males and related this to plasma concentrations of ASA. No adverse effects were found. A complete inhibition of serum thromboxane B₂ synthesis was demonstrated 5 min after injection of 100 mg ASA intravenously. ASA disappeared from the circulation within 60 min after bolus injection and at this time thromboxane B₂ synthesis was inhibited dose-dependently by 71%, 90% and 100% for doses of 25 mg, 50 mg and 100 mg, respectively. Inhibition of thromboxane B₂ synthesis after 100 mg of intravenous ASA was still 96.5% at 24 h and 93.4% at 48 h after the injection. The bleeding time measured at 30 min after ASA administration was significantly prolonged on the average by 70 s, 144 s and 211 s after 25 mg, 50 mg and 100 mg of ASA, respectively. Minor, but significant changes were found in tissue plasminogen activator antigen and in plasminogen activator inhibitor within the first hour after injection of low dose ASA, but similar changes were found after injection of saline. No change in tissue plasminogen activator activity was found. We conclude, that intravenous administration of low dose ASA is safe and easy, and that almost immediate, complete blockage of serum thromboxane B₂ synthesis can be obtained after a single intravenous bolus injection of 100 mg.

• References

• 1 Packham MA, Mustard JF. The role of platelets in the development and complications of atherosclerosis. Semin Haematol 1986; 23: 8-26
  PubMedGoogle Scholar
• 2 Kristensen SD, Martin JF. Platelet heterogeneity and coronary artery thrombosis. Platelets 1991; 2: 11-17
  CrossrefPubMedGoogle Scholar
• 3 Milner PC, Martin JF. Shortened bleeding time in myocardial infarction and its relation to platelet mass. Br Med J 1985; 290: 1767-1770
  CrossrefPubMedGoogle Scholar
• 4 Kristensen SD, Bath PMW, Martin JF. Differences in bleeding time, aspirin sensitivity and adrenaline between acute myocardial infarction and unstable angina. Cardiovasc Res 1990; 24: 19-23
  CrossrefPubMedGoogle Scholar
• 5 Henriksson P, Wennmalm A, Edhag O, Vesterquist O, Green K. In vivo production of prostacyclin and thromboxane in patients with acute myocardial infarction. Br Heart J 1986; 55: 543-548
  CrossrefPubMedGoogle Scholar
• 6 Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary artery disease. N Engl J Med 1986; 315: 983-989
  CrossrefPubMedGoogle Scholar
• 7 Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975; 56: 624-632
  PubMedGoogle Scholar
• 8 Fuster V, Badimon L, Badimon J, Adams PC, Turitto V, Chesebro JH. Drugs interfering with platelet functions: mechanisms and clinical relevance. Thrombosis and Haemostasis 1987 Leuven: Leuven University Press; 1987: 349-418
  Google Scholar
• 9 Husted SE, Nielsen HK. Platelet inhibitor agents in ischaemic heart disease. Myocardial Ischaemia Oxford: Blackwell Scientific Publications; Oxford: 1990: 352-369
  Google Scholar
• 10 Lewis HD, Davis JW, Archibald DG. et al Protective effect of aspirin against acute myocardial infarction and death in men with unstable angina. Results of Veteran Administration cooperative study. N Engl J Med 1983; 309: 396-403
  PubMedGoogle Scholar
• 11 Cairns JA, Gent M, Singer J. et al Aspirin, sulfinpyrazone or both in unstable angina. N Engl J Med 1985; 313: 1369-1375
  CrossrefPubMedGoogle Scholar
• 12 Theroux P, Quimet H, McCans J. et al Aspirin, heparin or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105-1111
  CrossrefPubMedGoogle Scholar
• 13 ISIS-2 collaborative group Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of acute myocardial infarction: ISIS-2. Lancet 1988 ii. 349-360
  PubMedGoogle Scholar
• 14 Husted SE, Nielsen HK, Krusell LR, Færgeman O. Acetylsalicylic acid 100 mg and 1000 mg daily in acute myocardial infarction suspects: a placebo-controlled trial. J Intern Med 1989; 226: 303-310
  CrossrefPubMedGoogle Scholar
• 15 Fitzgerald DJ, Catella F, Roy L, FitzGerald GA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988; 77: 142-150
  CrossrefPubMedGoogle Scholar
• 16 Menon IS. Aspirin and blood fibrinolysis. Lancet 1970; i: 364
  PubMedGoogle Scholar
• 17 Moroz LA. Increased blood fibrinolytic activity after aspirin ingestion. N Engl J Med 1977; 296: 525-529
  CrossrefPubMedGoogle Scholar
• 18 Mielke CH. Measurement of the bleeding time. Thromb Haemostas 1984; 52: 210-211
  PubMedGoogle Scholar
• 19 Gaspari F, Locatelli M. Determination of aspirin and salicylic acid in uremic patients plasma using reversed-phase high-performance liquid chromatography. Ther Drug Monitoring 1987; 9: 243-247
  CrossrefPubMedGoogle Scholar
• 20 Kræmmer Nielsen H, Christensen NJ, Husted SE. A new automated technique for platelet aggregation measurement. Scand J Clin Invest 1984; 44: 217-222
  CrossrefPubMedGoogle Scholar
• 21 Chmielewski J, Wiman B. Determination of tissue plasminogen activator and its “fast” inhibitor in plasma. Clin Chem 1986; 32: 482-485
  PubMedGoogle Scholar
• 22 Rånby M, Bergsdorf N, Nilsson T, Melbring G, Winblad B, Bucht G. Age dependence of tissue plasminogen activator concentrations in plasma as studied by an improved enzyme-linked immunosorbent assay. Clin Chem 1986; 32: 2160-2165
  PubMedGoogle Scholar
• 23 Siegel S. Non-Parametric Statistics for the Behavioral Science. New York: McGraw-Hill Book Company, Inc.; 1956
  Google Scholar
• 24 Rowland M, Riegelman S, Harris PA, Sholkoff SD, Eyring EJ. Kinetics of acetylsalicylic acid disposition in man. Nature 1967; 215: 413-414
  CrossrefPubMedGoogle Scholar
• 25 Wilson KM, Siebert DM, Duncan EM, Somogyi AA, Lloyd JV, Bochner F. Effect of aspirin infusions on platelet function in humans. Clin Sci 1990; 79: 37-42
  CrossrefPubMedGoogle Scholar
• 26 Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromoxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1366-1372
  CrossrefPubMedGoogle Scholar
• 27 Weksler BB, Tach-Goldman K, Subramanian VA, Gay WA. Cumulative inhibitory effect of low dose aspirin on vascular prostacyclin and platelet thromboxane production in patients with atherosclerosis. Circulation 1985; 71: 332-340
  CrossrefPubMedGoogle Scholar
• 28 Keber I, Jereb M, Keber D. Aspirin decreases fibrinolytic potential during venous occlusion, but not during acute physical activity. Thromb Res 1987; 46: 205-212
  CrossrefPubMedGoogle Scholar
• 29 Bounameaux H, Gresele P, Hanss M, De Cock F, Vermylen J, Collen D. Aspirin, indomethacin and dazoxiben do not affect the fibrinolytic activation induced by venous occlusion. Thromb Res 1985; 40: 161-170
  CrossrefPubMedGoogle Scholar
• 30 Hampton KK, Cerletti C, Loizou LA, Bucchi F, Donati MB, Davies JA, de Gaetano G, Prentice CRM. Coagulation, fibrinolytic and platelet function in patients on long-term therapy with aspirin 300 mg or 1,200 mg daily compared to placebo. Thromb Haemostas 1990; 64: 17-20
  PubMedGoogle Scholar
• 31 Angleton P, Chandler WL, Schmer G. Variation of tissue type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 1989; 79: 101-106
  CrossrefPubMedGoogle Scholar